The FDA has indicated that Vertex Pharmaceuticals’ experimental drug telaprevir cures more patients of hepatitis C than any current therapies, according to a Bloomberg report. 

Vertex is competing with Merck to win FDA clearance of a treatment for HVC.

“Overall, the FDA review team’s independent analyses confirmed the applicant’s primary efficacy findings and many secondary endpoint analyses for all pivotal clinical trials,” FDA staff reported.